Evusheld (designated in the study as AZD7442) is a monoclonal antibody mixture made up of 2 long-acting monoclonal antibodies tixagevimab (AZD8895) and cilgavimab (AZD1061). Currently, Evusheld has been granted a special import license by the Ministry of Health in Vietnam to meet the need for pre-exposure prophylaxis (prevention) of Covid-19 for high-risk subjects such as immunocompromised or unvaccinated people.Evusheld